Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden

Journal of Medical Economics

Volumn 16, Issue 12, 2013, Pages 1442-1452

  Ericsson, A ^a   Pollock, R F ^b   Hunt, B ^b   Valentine, W J ^b  

^a Novo Nordisk Scandinavia   (Sweden)

^b Ossian Health Economics and Communications   (Switzerland)

Author keywords

Cost utility; Costs and cost analysis; Diabetes mellitus; Insulin; Sweden

Indexed keywords

INSULIN DEGLUDEC; INSULIN GLARGINE;

ARTICLE; DRUG COST; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SELF MONITORING; SWEDEN;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SWEDEN;

EID: 84889869376     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.852099     Document Type: Article

References (35)

1. International Diabetes Federation. IDF Diabetes Atlas, 5th edn. Brussels, Belgium: International Diabetes Federation, 2011. http://www.idf.org/ diabetesatlas. Accessed September 3, 2013
2. Norberg M, Danielsson M. Overweight, cardiovascular diseases and diabetes: Health in Sweden: The National Public Health Report 2012. Scand J Public Health 2012;40(9 Suppl):135-63
3. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
5. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
6. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type diabetes. N Engl J Med 2008;358:2560-72
7. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
8. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes Care 2010;33(1 Suppl):S11-S61
9. Farcasiu E, Ivanyi T, Mozejko-Pastewka B, et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: A randomized, 16-week, open-label study. Clin Ther 2011;33:1682-93
10. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
11. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD005613
12. Child BP, Grothe JM, Greenleaf PJ. Strategies to limit the effect of hypoglycemia on diabetes control: Identifying and reducing the risks. Clin Diabetes 2012;30:28-33
13. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: A systematic review. Diabetes Metab Syndr Obes 2012;5:191-204
14. Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-50
15. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
16. Jonassen IB, Havelund S, Ribel U, et al. Insulin Degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Abstract presented at the American Diabetes Association 70th scientific sessions, Orlando, Florida, USA, June 25-29, 2010.
17. Tandvarrrr rds- och laddddkemedelsfoddddrmarrrr nsverket. Stockholm, 2013; http:// www.tlv.se/Upload/Beslut2013/bes130618-tresiba.pdf. Accessed September 3, 2013
18. Oddddstenson CG, Geelhoed-Duijvestijn P, Lahtela J, et al. Self-reported nonsevere hypoglycaemic events in Europe. Diabet Med 2013; published online 26 July 2013, doi: 10.1111/dme.12261
19. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:175-84
20. Sanofi-Aventis. Structure titration to target fasting glucose. Bidgewater, New Jersey, USA, 2007; http://www.lantus.com/hcp/dosing-titration/ titrationguide. aspx Accessed September 3, 2013
21. Philis-Tsimikas A, Brod M, Niemeyer M, et al. Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use). Adv Ther 2013;30:607-22
22. Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Jensen MM, et al. Effects of patient-reported non-severe hypoglycaemia on healthcare resource use and work-time loss in seven European Countries. Abstract presented at ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012.
23. Joddddnsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8
24. Statistiska centralbyrarrrr n. Konsumentprisindex (KPI). Stockholm, 2013; http:// www.scb.se/Pages/Product33769.aspx. Accessed September 3, 2013
25. Statistiska centralbyrarrrr n. Arbetskostnadsindex foddddr arbetare och tjaddddnstemaddddn inom privat sektor (AKI). Stockholm, 2013; http://www.scb.se/Pages/ TableAndChart248027.aspx. Accessed September 3, 2013
26. Statistiska centralbyrarrrr n. Arbetskostnadsindex foddddr arbetare och tjaddddnstemaddddn inom privat sektor (AKI). Stockholm, 2013; http://www.scb.se/Pages/ TableAndChart248029.aspx. Accessed September 3, 2013
27. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: A time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90
28. Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: Economic evaluation of data from the DiGEM trial. BMJ 2008;336:1177-80
29. Evans M, Jensen HH, Bøgelund M, et al. Flexible insulin dosing improves health-related quality of life (HRQoL) in a basal only treatment regimen: A time trade-off survey. Abstract presented at the American Diabetes Association 73rd scientific sessions, San Francisco, California, June 21-25, 2013
30. Holstein A, Plaschke A, Vogel MY, et al. Prehospital management of diabetic emergencies-a population-based intervention study. Acta Anaesthesiol Scand 2003;47:610-5
31. COMPUS. Optimal therapy recommendations for the prescribing and use of insulin analogues. Optimal Therapy Report CADTH 2009;3:(6)
32. Pfohl M, Schadddddlich PK, Dippel FW, et al. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. J Med Econ 2012;15(2 Suppl):14-27
33. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. Value Health 2012;15:632-8
34. Pollock RF, Curtis BH, Valentine WJ. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. J Med Econ 2012;15:766-75
35. Yang L, Christensen T, Sun F, et al. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: A health economic model based on the PREDICTIVE study. Value Health 2012;15(1 Suppl):S56-9